{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:16:55Z","timestamp":1783019815235,"version":"3.54.6"},"reference-count":15,"publisher":"Informa UK Limited","issue":"2","funder":[{"name":"Heed Ophthalmic Fellowship Foundation"},{"name":"McNamara Retina Research Fund"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Eye Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1080\/02713683.2025.2551165","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T08:19:26Z","timestamp":1756196366000},"page":"133-138","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated with Reference Ranibizumab for Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, or Retinal Vein Occlusion"],"prefix":"10.1080","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5429-0670","authenticated-orcid":false,"given":"Nikhil","family":"Bommakanti","sequence":"first","affiliation":[{"name":"Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Momenaei","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine Y.","family":"Wang","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl D.","family":"Regillo","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay E.","family":"Kuriyan","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Yonekawa","sequence":"additional","affiliation":[{"name":"Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01554-2"},{"key":"e_1_3_4_3_1","unstructured":"U.S. Food and Drug Administration. FDA approves first biosimilar to treat macular degeneration disease and other eye conditions [internet]. FDA; 2021 [cited 2023 Dec 14]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-biosimilar-treat-macular-degeneration-disease-and-other-eye-conditions."},{"key":"e_1_3_4_4_1","unstructured":"Food and Drug Administration. Biosimilar product information [internet]. Available from: https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information."},{"key":"e_1_3_4_5_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Scientific considerations in demonstrating biosimilarity to a reference product guidance for industry; April 2015 [cited 2025 Aug 21]. Available from https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003626"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.031"},{"key":"e_1_3_4_8_1","unstructured":"Coherus BioSciences. FDA approves Coherus\u2019 CIMERLITM (ranibizumab-eqrn) as the first and only interchangeable biosimilar to Lucentis\u00ae for all five indications with 12 months of interchangeability exclusivity | Coherus BioSciences Inc. [Internet]; 2023 [cited 2023 Dec 14]. Available from: https:\/\/investors.coherus.com\/news-releases\/news-release-details\/fda-approves-coherus-cimerlitm-ranibizumab-eqrn-first-and-only\/."},{"key":"e_1_3_4_9_1","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER). Considerations in demonstrating interchangeability with a reference product guidance for industry\u2019; 2019. Available from: https:\/\/www.fda.gov\/media\/124907\/download."},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02287-w"},{"key":"e_1_3_4_11_1","unstructured":"U.S. Food and Drug Administration. Interchangeable biological product [Internet]; 2023 [cited 2023 Dec 14]. Available from: https:\/\/www.fda.gov\/media\/151094\/download#:\u223c:text=Interchangeable%20Biosimilars -%E2%80%A2&text=An%20interchangeable%20biosimilar%20may%20be substituted%20for%20brand%2Dname%20drugs.&text=Not%20all%20biosimilars%20are%20interchangeable."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2176218"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.6.2.2"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.14659"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3181d87e04"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.3928\/23258160-20230508-01"}],"container-title":["Current Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/02713683.2025.2551165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T14:17:28Z","timestamp":1772720248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/02713683.2025.2551165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1080\/02713683.2025.2551165"],"URL":"https:\/\/doi.org\/10.1080\/02713683.2025.2551165","relation":{},"ISSN":["0271-3683","1460-2202"],"issn-type":[{"value":"0271-3683","type":"print"},{"value":"1460-2202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icey20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icey20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}